Hep C Virus - InterMune to Present at the 5th Annual JMP Securities Research Conference

InterMune to Present at the 5th Annual JMP Securities Research Conference
[Press Release] PR Newswire via Yahoo! Finance - Mar 02 1:01 PM
InterMune, Inc. announced today that Dan Welch, President and CEO of InterMune, will present a corporate overview at the 5th Annual JMP Securities Research Conference in San Francisco on Thursday, March 9, 2006 at 1:15 p.m.Save to My Web

MIGENIX Reports Third Quarter Fiscal Year 2006 Results
T-Net British Columbia - Mar 08 9:39 AM
Jim DeMesa, M.D., President & CEO of MIGENIX stated, "We continue to make excellent progress in our development programs, with two phase II clinical outcomes expected this year in our MX-3253 program for the treatment of chronic hepatitis C virus infections and a phase III clinical outcome for CPI-226 in catheter-related infections in the first half of calendar 2007. These outcomes have the Save to My Web

Human Genome Sciences Seen Partnering Hep C Drug In 2006
Forbes - Mar 16 10:32 AM
Piper Jaffray reiterated an "outperform" rating and $20 price target on the biotech firm.Save to My Web

Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary 2005 full year results: Good progress
n-tv.de - Mar 05 10:31 PM
Disclosure announcement transmitted by euro adhoc.Save to My Web